A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation

Sarina A. Piha-Paul, Chieh Tseng, Hai T. Tran, Meng Gao, Daniel D. Karp, Vivek Subbiah, Apostolia Maria Tsimberidou, Jitesh D. Kawedia, Siqing Fu, Shubham Pant, Timothy A. Yap, Van K. Morris, Bryan K. Kee, Mariela Blum Murphy, Jo Ann Lim, Funda Meric-Bernstam

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemistry